CHEN Yinghua 

(Department of Acupuncture and Moxibustion, First Affiliated Hospital of Heilongjiang University of Chinese Medicine ,Harbin, People’s Republic of China)

Abstract:  Objective: Pseudobulbar paralysis caused by ischemic stroke (PBP-IS)should be an urgent problem to be solved among the diseases of the nervous system. So far, modern medicine has not find an effective way to tackle this problem. Several studies suggest acupoint-injection may be applied to the treatment of pseudobulbar paralysis(PBP).However, current evidence is not enough to prove its efficacy. Therefore,this pilot study was desgined to certificate the feasibility and  validity  of  Xingnaojing  acupoint-injection  at  (XNJ-AI)  Fengchi(GB20)  for  treatment  of pseudobulbar paralysis caused by ischemic stroke (PBP-IS).  Methods: This study was an assessorblinded ,two-parallel-group, randomized controlled trial. Participants with (PBP-IS) was recruited and randomly divided into two groups .Participants in the controll group received the oral aspirin (one  100mg  tablet  once  a  day  for  two  weeks)  .In  addition  to  the  oral  aspirin  ,patients  in  the treatment group received Xingnaojing acupoint-injection(XNJ-AI) at Fengchi (GB20) (once a day for  two  weeks).Measures  was  taken  before  and  after  treatments.  The  primary  outcome  was assessed by the Kubota water experiment. The secondary outcome was to measure the TXB2and 6-keto-PGF1a.  Results:  We  observed  a  significantly  greater  improvement  in  swallowing function(P<0.05),and an obvious drop in the TXB2 values(P<0.05) with a remarkable rise in the 6-keto-PGF1a values(P<0.05).Conclusion: XNJ-AI at GB20 may improve the patients’ swallowing function and balance the TXB2and 6-keto-PGF1a.

Key  words:  Acupuncture  and  moxibustion,  Xingnaojing,  Acupoint-injection,  Pseudobulbar paralysis, Swallowing function, TXB2,6-keto-PGF1a